Long-acting PrEP | Department of Medicine Blog

Empowering Women’s PrEP Choices: Qualitative Insights into Long-Acting PrEP Preferences and Decision-Making during Pregnancy and Breastfeeding in South Africa and Botswana

Chen-Charles J, De Vos L, Vundhla P, Gebengu A, Rousseau E, Bekker LG, Peters R, Mussa A, Morroni C, Toska E, Babalola CM, Klausner J,[...]

By afschroeder • August 30, 2025

Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083

Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF,[...]

By sjmartinez • November 24, 2024

Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083

Mitchell KM, Boily MC, Hanscom B, Moore M, Todd J, Paz-Bailey G, Wejnert C, Liu A, Donnell DJ, Grinsztejn B, Landovitz RJ, Dimitrov DT. Estimating[...]

By sjmartinez • February 28, 2023